RNA Leaders

🧬RNA Leaders Industry Update🧬 ⭐ Versant Ventures and Novartis have launched Borealis Biosciences, Inc., a next generation RNA therapeutics company targeting kidney disease, with funding of $150M. 🔗https://lnkd.in/dbhUkksD ⭐ Exciting to see Abogen, Inc. have announced development of Cis-System -based circRNAs. 🔗 https://lnkd.in/eyvgQSp6 ⭐ BioNTech SE and Pfizer receive US FDA approval for Omicron KP.2-adapted COVID-19 Vaccine in individuals aged 6 months+. 🔗 https://lnkd.in/eM6mPGmD ⭐ Researchers at University of Rochester Medical Center and Indivumed Therapeutics have discovered a new way to classify distinct types of colon cancer based on RNA splicing events. 🔗 https://lnkd.in/ef4uweBf Come and join us in San Diego this September for RNA Leaders USA, where top industry leaders will share exciting updates!... 🎤 Raj Reddy, Canary Cure - Sharing insights into a novel RNA therapeutic approach to treating obesity 🎤 Rabia T. K., Serna Bio - Exploring the functional transcriptome 🎤 David Katzmann, Arrowhead Pharmaceuticals - Discussing the importance of receptor-ligand pairing for siRNA delivery 🔶 See the full 2024 agenda here: https://lnkd.in/eaHkSBNu #RNALeaders #mRNA #siRNA #nextgenRNA  

🧬RNA Leaders Industry Update🧬 ⭐ EnPlusOne Biosciences and the Wyss Institute at Harvard University have entered collaboration with up to $27M agreement by Advanced Research Projects Agency for Health (ARPA-H),  to progress a disease agnostic immunotherapeutic RNA platform with the potential to provide rapidly deployable treatment for cancer and infectious diseases. 🔗https://lnkd.in/g4VaBViy ⭐ Nuntius Therapeutics and Taiho Pharmaceutical Co., Ltd., announce partnership to advance cell-specific delivery of next-gen mRNA therapeutics. 🔗https://lnkd.in/gid9fah3 🔬 Denali Therapeutics announce publication of pre-clinical data in Science Translational Medicine highlighting the use of their oligonucleotide transfer vehicle platform to accomplish ASO delivery to the CNS and muscle following IV administration. 🔗 https://lnkd.in/edHCCNkg ⭐ Avidity Biosciences, Inc. announce proposed public offering of their common stock, with proceedings to be used for advancement of antibody oligonucleotide conjugate (AOC) clinical programs. 🔗 https://lnkd.in/e47uGAf2 Join us in San Diego this September for RNA Leaders USA, where top industry leaders will share more exciting updates! Hear from... 🎤 Gene Yeo, UC San Diego – Delving into RBP biology and RBP-RNA interactions 🎤 Daniel Fischer, Tevard Biosciences – Discussing the use of tRNA therapeutics to tackle genetic diseases 🎤 Brad Niles, ARIZ Precision Medicine – Exploring the design and delivery of PRDM2 siRNA for cancer 🔶 Secure your place this September here: https://lnkd.in/ewCpitZg #RNALeaders #RNAdelivery #ASO #siRNA #tRNA #RNAtherapeutics

📣 New Episode Alert: RNA Leaders Podcast Series! Dive into the latest RNA Leaders Podcast where Arcturus Therapeutics' Chief Strategy Officer, Roberta Duncan, MBA shares groundbreaking insights on mRNA technology and the future of therapeutics. Discover how their cutting-edge advancements with self-amplifying RNA could reshape healthcare as we know it. From innovative treatments to the challenges of the biotech industry, this episode is a must-listen for anyone passionate about the future of RNA. 📅 Plus, get a sneak peek into what Roberta will be discussing at the RNA Leaders event in less than three weeks in San Diego. Our final early bird is expiring tomorrow, so make sure you secure your part in the critical conversation happening in RNA. 👉 https://lnkd.in/dDBQQQVh  🔗 Listen now: https://lnkd.in/dsMefyJY #RNALeaders #Biotech #Pharma #HealthcareInnovation #Podcast #RNA #RNALeaders24 #healthcare #mRNA #therapeutics

🧬RNA Leaders Industry Update🧬 🔬 Fantastic to see Mass General Brigham's work on a phase 1 study of a neoantigen therapy at the investigational level. The individualized therapy is with encoded mRNA has shown that a patient’s immune system can target cancer cells. 🔗 https://lnkd.in/eqyzmGB6 🔬 Exciting to see University of Toronto researchers using CRISPR to manipulate and control RNA splicing precisely 🔗 https://lnkd.in/evre7Xp7 ⭐ Congratulations to Karius has obtaining a BARDA contract to develop RNA-based pathogens 🔗 https://lnkd.in/ekMhetC5 ⭐Great teamwork from the USP - Universidade de São Paulo on developing urinary mRNA-based biomarkers for non invasive bladder cancer 🔗 https://lnkd.in/ePFVSPfV Join us this September 4-5 for RNA Leaders USA, where top industry leaders will share more exciting updates!... 🎤 Tony Walshe, Alnylam Pharmaceuticals- Discussing the potential of siRNA for CNS targets. 🎤 Carter Palmer, Third Element Bio - Delving into a novel approach of RNA therapeutics to selectively control neuroinflammation 🎤 张巍怡, RiboX Therapeutics - Sharing insights on developing circular RNA as transformative medicine. 🔶 Confirm your place in San Diego here!: https://lnkd.in/dhTfJ4VB

🧬RNA Leaders Industry Update🧬 🔬 Exciting to see Myeloid Therapeutics has initiated patient dosing of its second clinical in vivo mRNA CAR program, MT-303, against advanced hepatocellular carcinoma. 🔗 https://lnkd.in/endr_kFe ⭐ Congratulations to AIRNA who have raised a further $60M, taking their series A round to $90M. The proceeds will be used to progress AIRNA's lead RNA editing candidate for the treatment of alpha-1 antitrypsin deficiency into the clinic. 🔗 https://lnkd.in/dyFacVDZ 🔬 Fantastic to see BioNTech SE have announced positive topline phase 2 results for its mRNA immunotherapy candidate BNT11, in combination with Regeneron's anti-PD-1 monoclonal antibody cemipilimab in patients with advanced melanoma. 🔗 https://lnkd.in/ecxWAdZQ ⭐ SINERGIUM Biotech supported by World Health Organization & Medicines Patent Pool, launch a new initative to accelerate mRNA vaccine candidate development against human avian influenza (H5N1) for manufactures in low- and middle-income countries. 🔗 https://lnkd.in/ddZkPb76) Join us this September 4-5 for RNA Leaders USA, where top industry leaders will share more exciting updates!... 🎤 Karin Jooss, Gritstone bio - Discussing the potential of saRNA to target advanced metastatic solid tumours. 🎤 Todd Chappell, Korro Bio, Inc. - Delving into a novel ADAR editing platform, OPERA (Oligonucleotide Promoted Editing of RNA) to treat liver and CNS disease. 🎤 Rachel Groppo, Johnson & Johnson - Sharing insights on accelerating discovery of saRNA vaccines and therapeutics. 🔶 Confirm your place in San Diego here!: https://lnkd.in/ewCpitZg #RNALeaders #RNAediting #ADAR #mRNAimmunotherapy

🎉 Happy World RNA Day from #RNALeaders! 🎉 Today, we're celebrating the incredible advancements in #RNA technology, from groundbreaking therapeutics to life-saving vaccines and beyond. Join us at our next event this September in San Diego to continue the celebration and exploration of RNA innovations. #RNAday Find out more here: https://lnkd.in/e3v_CJp5

I will be speaking at RNA Leaders USA, taking place on September 4-5, 2024. Join me to accelerate innovation and commercialisation of #RNA therapeutics and vaccines #RNALeaders https://lnkd.in/gXaKFy2C RNA Leaders

🧬RNA Leaders Industry Update🧬 🔬 Congratulations to Ionis Pharmaceuticals, Inc. who have announced positive data from the HALOS study of ION582 in Angelman syndrome patients. 🔗 https://lnkd.in/eR352MUJ ⭐ Exciting to see BioNTech SE and Triastek, Inc. have entered a partnership focusing on advancement of 3D-printed oral RNA therapeutics. 🔗 https://lnkd.in/eeRdYHAu   ⭐ European Medicines Agency drafts new guidelines addressing the manufacturing, characterization and analytical control of oligonucleotide drugs. 🔗 https://lnkd.in/eF992Etq 🔬 Congratulations to Steve Pascolo and team at the Universitätsspital Zürich on the publish of their new article focussed on immune-chemotherapeutic RNA and its potential in cancer treatment. 🔗 https://lnkd.in/eRpqWS_8 ⭐ ST PHARM enters a ₩14 billion supply agreement for oligo APIs, for three of its oligo-based therapeutics 🔗 https://lnkd.in/eM2a9pa8 ⭐ Congratulations to Vicente Godoy on his promotion to VP Quality Management & Compliance ay Cardior Pharmaceuticals 🔗 https://lnkd.in/eD4MtXBt Come join us in San Diego this September for RNA Leaders USA, where top industry leaders will share more exciting updates!... 🎤 James McArthur, CEO, PepGen – Exploring the use of peptide-conjugated oligos targeting neuromuscular disorders 🎤 Jarret Glasscock, CEO, Cofactor Genomics – Sharing insight on multidimensional RNA diagnostics to predict immunotherapy patient outcomes 🎤 Kasper Roet, CEO, QurAlis – Discussing ASO development via FlexASO to regulate pathogenic protein expression associated with ALS 🔶 See the full 2024 agenda here: https://lnkd.in/eaHkSBNu #RNALeaders #ASO #RNAi #RNAtherapeutics

📣 New Episode Alert: RNA Leaders Podcast Series!   In this week's episode, Jade Osei-Tutu from LSX sits down with Jacob Petersen, SVP, Global Head of Nucleic Acid Therapeutics at Novo Nordisk. They discuss the future of RNA technologies, the shift from rare to common diseases, and the importance of sustainable manufacturing practices.   Jacob shares his journey from biochemistry to leading innovations in RNA therapeutics, emphasizing the need for cost-effective, environmentally-friendly production methods to make these therapies accessible to millions.   Don't miss out on this insightful conversation and learn what’s next for RNA therapies! 📅 Plus, get a sneak peek into what Jacob will be discussing at the RNA Leaders event this September in San Diego.   🔗 Listen now:https://lnkd.in/dUQuPT_v #RNALeaders #NovoNordisk #Biotech #Pharma #HealthcareInnovation #Podcast #RNA #RNALeaders24

🧬RNA Leaders Industry Update🧬 ⭐ Congratulations to Rona Therapeutics on their completion of $35M series A+ funding round, to advance their metabolic siRNA pipeline and CNS delivery platform into clinical development. 🔗 https://lnkd.in/eB5z9F46... ⭐ Exciting developments in RNA editing made by researchers at from Weixin Tang group at University of Chicago, who report a novel platform, DECOR (deaminase-enabled recoding of RNA), which enables targeted A-I editing to CRISPR-specified sites with reduced off-target effects. 🔗 https://lnkd.in/eYNWF7AY 🔬 Great to see Rznomics Inc. will start its Phase I/II clinical trial of RZ-004, an RNA editing therapy for treatment of retinitis pigmentosa. 🔗 https://lnkd.in/eqn9Ca5A ⭐ Congratulations to ARGONAUTE RNA LIMITED who have raised £1.75M to advance their siRNA pipeline against severe familial hypercholesterolaemia. 🔗 https://lnkd.in/ePNa8gxN ⭐Fantastic to see the Wyss Institute at Harvard University has been awarded $27M by the Advanced Research Projects Agency for Health (ARPA-H), to progress their new RNA therapeutics for cancer and infectious disease towards IND approval. 🔗 https://lnkd.in/e7T-e2hD Come and join us in San Diego this September for RNA Leaders USA, where top industry leaders will share more exciting updates!... 🎤 Josh Mandel-Brehm, CAMP4 Therapeutics – Delving into the use of regRNA as a new target in CNS and metabolic diseases 🎤 Vignesh Narayan Hariharan, University of Massachusetts Amherst – Sharing insight into siRNA design for optimal CNS accumulation and silencing 🎤 David Huss, Shape Therapeutics Inc. – Exploring ADAR-based editing in the CNS using the RNAfix platform 🔶 You can view the full speaker line-up at RNA Leaders USA 2024 here: https://lnkd.in/eZA3Rvwz #RNALeaders #RNA #siRNA #ADAR #regRNA